Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price target of $10.00 for the company, according to Zacks. Zacks has also assigned Adamis Pharmaceuticals Corp. an industry rank of 97 out of 265 based on the ratings given to its competitors.
Separately, Maxim Group set a $10.00 price target on Adamis Pharmaceuticals Corp. and gave the stock a “buy” rating in a research report on Monday, September 19th.
Shares of Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) traded down 1.20% during mid-day trading on Wednesday, hitting $3.28. 63,819 shares of the stock were exchanged. The stock’s 50 day moving average is $3.03 and its 200 day moving average is $4.83. The firm’s market cap is $68.51 million. Adamis Pharmaceuticals Corp. has a 12 month low of $2.50 and a 12 month high of $10.98.
Institutional investors have recently made changes to their positions in the stock. Walleye Trading LLC raised its position in shares of Adamis Pharmaceuticals Corp. by 118.1% in the second quarter. Walleye Trading LLC now owns 275,078 shares of the specialty pharmaceutical company’s stock valued at $770,000 after buying an additional 148,966 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Adamis Pharmaceuticals Corp. by 24.7% in the second quarter. BlackRock Fund Advisors now owns 49,806 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 9,868 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Adamis Pharmaceuticals Corp. by 21.8% in the second quarter. Vanguard Group Inc. now owns 335,814 shares of the specialty pharmaceutical company’s stock valued at $940,000 after buying an additional 60,197 shares in the last quarter. Hedge funds and other institutional investors own 9.70% of the company’s stock.
Adamis Pharmaceuticals Corp. Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp. and related companies with MarketBeat.com's FREE daily email newsletter.